2018
DOI: 10.3386/w24769
|View full text |Cite
|
Sign up to set email alerts
|

Not in the job description: The commercial activities of academic scientists and engineers

Abstract: Scholarly work seeking to understand academics' commercial activities often draws on abstract notions of the institution of science and of the representative scientist. Few scholars have examined whether and how scientists' motives to engage in commercial activities differ across fields. Similarly, efforts to understand academics' choices have focused on three self-interested motivesrecognition, challenge, and moneyignoring the potential role of the desire to have an impact on others. Using panel data for a na… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2021
2021

Publication Types

Select...
1
1

Relationship

2
0

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 61 publications
(114 reference statements)
0
1
0
Order By: Relevance
“…Faced with the pressures to (re-) apply for funding, they adjust their research 16 Rewards also include the satisfaction derived from puzzle solving, and financial gain that often accompanies a successful research career (Stephan 2012;Stephan and Levin 1992). Cohen, Sauermann and Stephan (2020) also show that scientists are strongly motivated by an interest in contributing to society. 17 Jim Allison, who shared the Nobel Prize for immunotherapy for cancer in 2018 is but one case in point.…”
Section: Principal Investigatorsmentioning
confidence: 91%
“…Faced with the pressures to (re-) apply for funding, they adjust their research 16 Rewards also include the satisfaction derived from puzzle solving, and financial gain that often accompanies a successful research career (Stephan 2012;Stephan and Levin 1992). Cohen, Sauermann and Stephan (2020) also show that scientists are strongly motivated by an interest in contributing to society. 17 Jim Allison, who shared the Nobel Prize for immunotherapy for cancer in 2018 is but one case in point.…”
Section: Principal Investigatorsmentioning
confidence: 91%